GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth

GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.

Zacks Investment Research • 9 hours ago

GRAIL to Present at the UBS Global Healthcare Conference

SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, Nov. 10 at 11:00 a.m.

PRNewsWire • Oct 27, 2026

5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps

The S&P 500 recently sat just 2.5% below its all-time high. Look past the index, though, and the picture gets uglier.

MarketBeat • Oct 26, 2026

GRAIL to Announce Third Quarter 2026 Financial Results

SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026.

PRNewsWire • Oct 21, 2026

11 Stocks Most Likely to See a Short Squeeze Rally

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.

Schaeffers Research • Oct 12, 2026

Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.

Grail's stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri's success.

The Motley Fool • Oct 11, 2026

2 Growth Stocks to Buy in October

Grail's stock could skyrocket if the FDA approves Galleri. Veeva's life sciences CRM business is still growing at a steady rate.

The Motley Fool • Oct 8, 2026

Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase

Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices, and figuring out which side each sits on changes everything about whether to buy.

24/7 Wall Street • Oct 7, 2026

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain taking place Oct. 23-27, 2026.

PRNewsWire • Oct 5, 2026

Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?

Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.

The Motley Fool • Oct 4, 2026